Zymeworks Inc. (ZYME)

8.06 -0.05 (-0.62%) As of 10:59AM EDT. Market open.

Zymeworks Inc.

108 Patriot Drive
Suite A
Middletown, DE 19709
United States
(302) 274-8744
https://www.zymeworks.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 272

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kenneth H. Galbraith C.A.	Chairman, CEO & Interim CFO	1.04M	N/A	1963
Dr. Paul Moore Ph.D.	Chief Scientific Officer	872.67k	N/A	1968
Mr. Mark Hollywood	Executive VP and Head of Technical & Manufacturing Operations	N/A	N/A	1970
Mr. Daniel Dex J.D., Ph.D.	Senior VP, Corporate Secretary & General Counsel	N/A	N/A	N/A
Diana Papove	Senior Manager of Corporate Communications	N/A	N/A	N/A
Dr. Lindsey Foulkes B.Sc., Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Ms. Laura O'Connor	Vice President of Human Resources & DEI	N/A	N/A	N/A
Dr. Jeffrey Smith M.D.	Executive VP & Chief Medical Officer	N/A	N/A	N/A
Dr. Josemund Menezes MBBS	Managing Director of Early-Stage Development for Asia Pacific	N/A	N/A	N/A
Mr. John Fann Ph.D.	Senior Vice President of Process Sciences	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Corporate governance

Zymeworks Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.